PreciGen, Inc. Files 2023 Annual Report on Form 10-K

Ticker: PGEN · Form: 10-K · Filed: Mar 19, 2024 · CIK: 1356090

Precigen, Inc. 10-K Filing Summary
FieldDetail
CompanyPrecigen, Inc. (PGEN)
Form Type10-K
Filed DateMar 19, 2024
Risk Levelmedium
Pages15
Reading Time17 min
Sentimentneutral

Sentiment: neutral

Topics: 10-K, Annual Report, PreciGen, PGEN, Pharmaceuticals

TL;DR

<b>PreciGen, Inc. has filed its 2023 10-K report detailing its operations and financial standing.</b>

AI Summary

PRECIGEN, INC. (PGEN) filed a Annual Report (10-K) with the SEC on March 19, 2024. PreciGen, Inc. filed its annual report on Form 10-K for the fiscal year ended December 31, 2023. The filing covers the period from January 1, 2023, to December 31, 2023. The company's principal business address is located at 20374 Seneca Meadows Parkway, Germantown, MD 20876. PreciGen, Inc. was formerly known as Intrexon Corp, with a name change effective March 13, 2006. The company operates within the Pharmaceutical Preparations industry (SIC code 2834).

Why It Matters

For investors and stakeholders tracking PRECIGEN, INC., this filing contains several important signals. This 10-K filing provides a comprehensive overview of PreciGen's business, financial performance, and risk factors for the fiscal year 2023, which is crucial for investors to assess the company's current health and future prospects. Understanding the company's historical financial data, segment performance, and executive compensation detailed in this report is essential for making informed investment decisions regarding PreciGen, Inc.

Risk Assessment

Risk Level: medium — PRECIGEN, INC. shows moderate risk based on this filing. The company's financial performance and operational risks are not detailed in the provided snippet, requiring a deeper review of the full 10-K to assess the overall risk level.

Analyst Insight

Investors should review the full 10-K filing to understand PreciGen's financial performance, strategic initiatives, and risk factors for 2023.

Key Numbers

  • 2023-12-31 — Fiscal Year End (Conformed period of report)
  • 2024-03-19 — Filing Date (Filed as of date)
  • 2023-01-01 — Reporting Period Start (Fiscal year 2023 start date)
  • 2022-12-31 — Prior Year End (Comparison period)

Key Players & Entities

  • PRECIGEN, INC. (company) — Filer name
  • PGEN (company) — Ticker symbol
  • 20374 SENECA MEADOWS PARKWAY (location) — Business address street
  • Germantown (location) — Business address city
  • MD (location) — Business address state
  • 20876 (location) — Business address zip
  • INTREXON CORP (company) — Former company name
  • 2834 (industry) — Standard Industrial Classification

FAQ

When did PRECIGEN, INC. file this 10-K?

PRECIGEN, INC. filed this Annual Report (10-K) with the SEC on March 19, 2024.

What is a 10-K filing?

A 10-K is a comprehensive annual financial report required by the SEC, covering audited financials, business operations, risk factors, and management discussion. This particular 10-K was filed by PRECIGEN, INC. (PGEN).

Where can I read the original 10-K filing from PRECIGEN, INC.?

You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by PRECIGEN, INC..

What are the key takeaways from PRECIGEN, INC.'s 10-K?

PRECIGEN, INC. filed this 10-K on March 19, 2024. Key takeaways: PreciGen, Inc. filed its annual report on Form 10-K for the fiscal year ended December 31, 2023.. The filing covers the period from January 1, 2023, to December 31, 2023.. The company's principal business address is located at 20374 Seneca Meadows Parkway, Germantown, MD 20876..

Is PRECIGEN, INC. a risky investment based on this filing?

Based on this 10-K, PRECIGEN, INC. presents a moderate-risk profile. The company's financial performance and operational risks are not detailed in the provided snippet, requiring a deeper review of the full 10-K to assess the overall risk level.

What should investors do after reading PRECIGEN, INC.'s 10-K?

Investors should review the full 10-K filing to understand PreciGen's financial performance, strategic initiatives, and risk factors for 2023. The overall sentiment from this filing is neutral.

How does PRECIGEN, INC. compare to its industry peers?

PreciGen, Inc. operates in the Pharmaceutical Preparations industry, focusing on the development and commercialization of therapeutic products.

Are there regulatory concerns for PRECIGEN, INC.?

As a publicly traded company, PreciGen, Inc. is subject to the reporting requirements of the Securities and Exchange Commission (SEC), including the filing of annual reports on Form 10-K.

Industry Context

PreciGen, Inc. operates in the Pharmaceutical Preparations industry, focusing on the development and commercialization of therapeutic products.

Regulatory Implications

As a publicly traded company, PreciGen, Inc. is subject to the reporting requirements of the Securities and Exchange Commission (SEC), including the filing of annual reports on Form 10-K.

What Investors Should Do

  1. Review the full 10-K for detailed financial statements and performance metrics.
  2. Analyze the risk factors section to understand potential challenges facing PreciGen.
  3. Examine any disclosures regarding executive compensation and corporate governance.

Key Dates

  • 2023-12-31: Fiscal Year End — End of the reporting period for the 10-K.
  • 2024-03-19: Filing Date — Date the 10-K was officially filed with the SEC.

Year-Over-Year Comparison

This is the initial filing snippet provided for the 2023 10-K; comparative data from the previous filing is not available in this extract.

Filing Stats: 4,370 words · 17 min read · ~15 pages · Grade level 17 · Accepted 2024-03-19 16:48:47

Filing Documents

Risk Factors

Item 1A. Risk Factors 42

Unresolved Staff Comments

Item 1B. Unresolved Staff Comments 70

Properties

Item 2. Properties 71

Legal Proceedings

Item 3. Legal Proceedings 72

Mine Safety Disclosures

Item 4. Mine Safety Disclosures 72 PART II

Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities

Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 73

[Reserved]

Item 6. [Reserved] 75

Management's Discussion and Analysis of Financial Condition and Results of Operations

Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations 75

Quantitative and Qualitative Disclosures About Market Risk

Item 7A. Quantitative and Qualitative Disclosures About Market Risk 85

Financial Statements and Supplementary Data

Item 8. Financial Statements and Supplementary Data 85

Changes in and Disagreements with Accountants on Accounting and Financial Disclosure

Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure 85

Controls and Procedures

Item 9A. Controls and Procedures 85

Other Information

Item 9B. Other Information 86

Disclosure Regarding Foreign Jurisdictions that Prevent Inspections

Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections 86 PART III

Directors, Executive Officers and Corporate Governance

Item 10. Directors, Executive Officers and Corporate Governance 87

Executive Compensation

Item 11. Executive Compensation 87

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 87

Certain Relationships and Related Transactions, and Director Independence

Item 13. Certain Relationships and Related Transactions, and Director Independence 87

Principal Accountant Fees and Services

Item 14. Principal Accountant Fees and Services 87 PART IV

Exhibits and Financial Statement Schedules

Item 15. Exhibits and Financial Statement Schedules 88

Form 10-K Summary

Item 16. Form 10-K Summary 90 ________________________ Precigen , AdenoVerse , UltraCAR-T , RheoSwitch , UltraVector , RTS , UltraPorator , ActoBiotics and RheoSwitch Therapeutic System are our and/or our affiliates' registered trademarks in the United States and GenVec, ActoBio Therapeutics, AttSite, and Precigen Therapeutics are our and/or our affiliates' common law trademarks in the United States are our and/or our affiliates' common law trademarks in the United States. This Annual Report on Form 10-K, or Annual Report, and the information incorporated herein by reference contain references to trademarks, service marks, and trade names owned by us or other companies. Solely for convenience, trademarks, service marks, and trade names referred to in this Annual Report and the information incorporated herein, including logos, artwork, and other visual displays, may appear without the or symbols, but such references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or the rights of the applicable licensor to these trademarks, service marks, and trade names. We do not intend our use or display of other companies' trade names, service marks, or trademarks to imply a relationship with, or endorsement or sponsorship of us by, any other companies. Other trademarks, trade names, and service marks appearing in this Annual Report are the property of their respective owners. Unless the context requires otherwise, references in this Annual Report to "Precigen", "we", "us", and "our" refer to Precigen, Inc. 3 Table of Contents Special Note Regarding Forward-Looking Statements This Annual Report contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which statements involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this Annual Report, including statements regarding our strategy

Business

Item 1. Business Overview We are a dedicated discovery and clinical-stage biopharmaceutical company advancing the next generation of gene and cell therapies with the overall goal of improving outcomes for patients with significant unmet medical needs. We are leveraging our proprietary technology platforms to develop product candidates designed to target urgent and intractable diseases in our core therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. We have developed an extensive pipeline of therapies across multiple indications. We believe that our array of technology platforms uniquely positions us among other biotechnology companies to advance precision medicine. Precision medicine is the practice of therapeutic product development that takes into account specific genetic variations within populations impacted by a disease to design targeted therapies to improve outcomes for a disease or patient population. Our proprietary and complementary technology platforms provide a strong foundation to realize the core promise of precision medicine by supporting our efforts to construct powerful gene programs to drive efficacy, deliver these programs through viral, non-viral, and microbe-based approaches to drive lower costs, and control gene expression to drive safety. Our therapeutic platforms, including UltraCAR-T, AdenoVerse immunotherapy, and ActoBiotics, are designed to allow us to precisely control the level and physiological location of gene expression and modify biological molecules to control the function and output of living cells to treat underlying disease conditions. We are actively advancing our lead clinical programs, including: PRGN-3005, PRGN-3006, and PRGN-3007, which are built on our UltraCAR-T platform; PRGN-2009 and PRGN-2012, which are based on our AdenoVerse immunotherapy platform. In addition, we have completed a Phase 1b/2a study of AG019, which is built on our ActoBiotics platform. We also have a robust pipeline

View Full Filing

View this 10-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.